CRISPR Gene Activation Rescues Severe Neurodevelopmental Disorders in Mice

This groundbreaking study demonstrates that CRISPR activation (CRISPRa) can successfully treat neurodevelopmental disorders caused by haploinsufficiency, where only one of two gene copies functions properly. The researchers focused on SCN2A, a gene whose loss causes severe autism, intellectual disability, and treatment-resistant seizures in approximately 1 in 12,000 births.

Using mice with SCN2A haploinsufficiency, the team delivered CRISPR components via adeno-associated virus (AAV) to boost expression of the remaining functional gene copy. The treatment targeted the gene's promoter region to increase production of Nav1.2, a crucial sodium channel protein essential for brain cell electrical activity.

The results were remarkable: CRISPRa restored normal electrical properties in brain cells, corrected synaptic deficits, and protected mice against chemically-induced seizures. Importantly, the treatment remained effective even when administered during adolescence, suggesting that intervention doesn't need to occur in early development to be beneficial.

The researchers validated their approach in human stem cell-derived neurons with SCN2A mutations, demonstrating restored electrical excitability. RNA sequencing confirmed that the treatment specifically targeted SCN2A without significant off-target effects, addressing a key safety concern.

This approach could revolutionize treatment for genetic brain disorders. Traditional gene therapy is limited by the small cargo capacity of AAV vectors, excluding 117 of 227 known haploinsufficient neurodevelopmental disorder genes. CRISPRa circumvents this limitation by activating existing genes rather than delivering new copies, opening therapeutic possibilities for previously untreatable conditions.